231 related articles for article (PubMed ID: 28585223)
1. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
[TBL] [Abstract][Full Text] [Related]
2. The molecular tweezer CLR01 reduces aggregated, pathologic, and seeding-competent α-synuclein in experimental multiple system atrophy.
Herrera-Vaquero M; Bouquio D; Kallab M; Biggs K; Nair G; Ochoa J; Heras-Garvin A; Heid C; Hadrovic I; Poewe W; Wenning GK; Klärner FG; Schrader T; Bitan G; Stefanova N
Biochim Biophys Acta Mol Basis Dis; 2019 Nov; 1865(11):165513. PubMed ID: 31319154
[TBL] [Abstract][Full Text] [Related]
3. CLR01 protects dopaminergic neurons in vitro and in mouse models of Parkinson's disease.
Bengoa-Vergniory N; Faggiani E; Ramos-Gonzalez P; Kirkiz E; Connor-Robson N; Brown LV; Siddique I; Li Z; Vingill S; Cioroch M; Cavaliere F; Threlfell S; Roberts B; Schrader T; Klärner FG; Cragg S; Dehay B; Bitan G; Matute C; Bezard E; Wade-Martins R
Nat Commun; 2020 Sep; 11(1):4885. PubMed ID: 32985503
[TBL] [Abstract][Full Text] [Related]
4. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
Fleming SM; Mulligan CK; Richter F; Mortazavi F; Lemesre V; Frias C; Zhu C; Stewart A; Gozes I; Morimoto B; Chesselet MF
Mol Cell Neurosci; 2011 Mar; 46(3):597-606. PubMed ID: 21193046
[TBL] [Abstract][Full Text] [Related]
5. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
[TBL] [Abstract][Full Text] [Related]
6. Chronic administration of cholesterol oximes in mice increases transcription of cytoprotective genes and improves transcriptome alterations induced by alpha-synuclein overexpression in nigrostriatal dopaminergic neurons.
Richter F; Gao F; Medvedeva V; Lee P; Bove N; Fleming SM; Michaud M; Lemesre V; Patassini S; De La Rosa K; Mulligan CK; Sioshansi PC; Zhu C; Coppola G; Bordet T; Pruss RM; Chesselet MF
Neurobiol Dis; 2014 Sep; 69():263-75. PubMed ID: 24844147
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
8. Brain infusion of α-synuclein oligomers induces motor and non-motor Parkinson's disease-like symptoms in mice.
Fortuna JTS; Gralle M; Beckman D; Neves FS; Diniz LP; Frost PS; Barros-Aragão F; Santos LE; Gonçalves RA; Romão L; Zamberlan DC; Soares FAA; Braga C; Foguel D; Gomes FCA; De Felice FG; Ferreira ST; Clarke JR; Figueiredo CP
Behav Brain Res; 2017 Aug; 333():150-160. PubMed ID: 28668282
[TBL] [Abstract][Full Text] [Related]
9. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
10. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
11. A GCase chaperone improves motor function in a mouse model of synucleinopathy.
Richter F; Fleming SM; Watson M; Lemesre V; Pellegrino L; Ranes B; Zhu C; Mortazavi F; Mulligan CK; Sioshansi PC; Hean S; De La Rosa K; Khanna R; Flanagan J; Lockhart DJ; Wustman BA; Clark SW; Chesselet MF
Neurotherapeutics; 2014 Oct; 11(4):840-56. PubMed ID: 25037721
[TBL] [Abstract][Full Text] [Related]
12. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
13. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein.
Fleming SM; Tetreault NA; Mulligan CK; Hutson CB; Masliah E; Chesselet MF
Eur J Neurosci; 2008 Jul; 28(2):247-56. PubMed ID: 18702696
[TBL] [Abstract][Full Text] [Related]
14. Immunolocalization of human alpha-synuclein in the Thy1-aSyn ("Line 61") transgenic mouse line.
Delenclos M; Carrascal L; Jensen K; Romero-Ramos M
Neuroscience; 2014 Sep; 277():647-64. PubMed ID: 25090921
[TBL] [Abstract][Full Text] [Related]
15. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.
Paumier KL; Luk KC; Manfredsson FP; Kanaan NM; Lipton JW; Collier TJ; Steece-Collier K; Kemp CJ; Celano S; Schulz E; Sandoval IM; Fleming S; Dirr E; Polinski NK; Trojanowski JQ; Lee VM; Sortwell CE
Neurobiol Dis; 2015 Oct; 82():185-199. PubMed ID: 26093169
[TBL] [Abstract][Full Text] [Related]
16. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
Zhou W; Milder JB; Freed CR
J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
[TBL] [Abstract][Full Text] [Related]
17. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
18. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein.
Fleming SM; Salcedo J; Hutson CB; Rockenstein E; Masliah E; Levine MS; Chesselet MF
Neuroscience; 2006 Nov; 142(4):1245-53. PubMed ID: 16934409
[TBL] [Abstract][Full Text] [Related]
19. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein.
Fleming SM; Salcedo J; Fernagut PO; Rockenstein E; Masliah E; Levine MS; Chesselet MF
J Neurosci; 2004 Oct; 24(42):9434-40. PubMed ID: 15496679
[TBL] [Abstract][Full Text] [Related]
20. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.
Hartlage-Rübsamen M; Bluhm A; Moceri S; Machner L; Köppen J; Schenk M; Hilbrich I; Holzer M; Weidenfeller M; Richter F; Coras R; Serrano GE; Beach TG; Schilling S; von Hörsten S; Xiang W; Schulze A; Roßner S
Acta Neuropathol; 2021 Sep; 142(3):399-421. PubMed ID: 34309760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
